Clinical Trial Liability Insurance in Connecticut

Connecticut at a glance

Primary regulator

Connecticut Insurance Department

Oversees insurer licensing and form filings for coverage written in the state.

Research concentration

Hartford-New Haven academic medical corridor

Weighted toward investigator-initiated oncology, cardiovascular, and pediatric trials.

Consent standard

General medical-negligence and informed-consent case law

Connecticut has no standalone human-subjects research statute; courts apply reasonable-patient disclosure standards.

Investigator role

Frequent investigator-as-sponsor structure for investigator-initiated trials

Shifts FDA sponsor-level duties and liability exposure onto the principal investigator.

Hartford-New Haven research corridor

The corridor running from Hartford's insurance-and-health hub down to New Haven's academic medical center creates a research base weighted toward oncology, cardiovascular, and pediatric investigator-initiated trials rather than the large industry-sponsored Phase III volume seen in bigger pharma states. That mix means a meaningful share of Connecticut exposure sits with the principal investigator and the academic institution rather than with an outside sponsor, so coverage decisions often turn on how the institution's own indemnification obligations interact with any sponsor-provided policy.

Informed consent through Connecticut medical-negligence law

Connecticut does not maintain a codified human-subjects research statute comparable to some neighboring states; instead, courts apply the state's general medical-negligence and lack-of-informed-consent framework to research injury claims, judging disclosure against what a reasonable patient in the participant's position would need to know. Investigators should treat the consent discussion as clinical documentation subject to the same negligence exposure as any other treatment decision, since Connecticut plaintiffs' bar frequently frames trial injury suits in exactly those terms.

Investigator-initiated trial exposure

Because so much Connecticut activity is investigator-initiated rather than sponsor-driven, the principal investigator often functions as the de facto sponsor for regulatory and liability purposes, taking on FDA sponsor obligations, safety reporting, and monitoring duties that a purely industry-funded site would delegate outward. That role shift changes the underwriting conversation: a policy sized for a participating site in a large multicenter trial will not automatically reflect the broader duties an investigator-sponsor carries.

Structuring coverage for a Connecticut program

A Connecticut program should coordinate clinical trial liability with medical professional liability for the investigator, products/completed-operations coverage where an investigational device or biologic is involved, and cyber coverage for participant data given the state's breach-notification requirements. Confirm current consent standards and investigator-sponsor obligations with a knowledgeable attorney before setting limits, since the investigator-initiated posture of much Connecticut research changes who bears primary responsibility.

Who we write this for in Connecticut

Clinical trial liability FAQs for Connecticut